Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Phase 1

Terminated

Conditions: Squamous Non-small Cell Lung Cancer

Interventions: Drug: Buparlisib
Drug: Buparlisib matching placebo
Drug: Docetaxel

First Posted Date: 2013-07-30

Last Posted Date: 2018-08-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT01911325

Locations: 🇺🇸
Reliant Medical Group Reliant Medical Group, Worcester, Massachusetts, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt, Tampa, Florida, United States
🇺🇸
Highlands Oncology Group SC-1, Fayetteville, Arkansas, United States

and more 2 locations

A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: LM716

First Posted Date: 2013-07-30

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01911936

Locations: 🇯🇵
Novartis Investigative Site, Fukuoka, Japan

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

Phase 4

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Vildagliptin
Drug: Glimepiride
Drug: Metformin

First Posted Date: 2013-07-29

Last Posted Date: 2015-10-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT01910441

An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.

Phase 3

Completed

Conditions: Glaucoma, Neovascular
Choroidal Neovascularization
Diabetic Retinopathy
Macular Edema

Interventions: Drug: ranibizumab

First Posted Date: 2013-07-26

Last Posted Date: 2019-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 270

Registration Number: NCT01908816

Locations: 🇫🇷
Novartis Investigative Site, Vannes, France

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: BAF312

First Posted Date: 2013-07-22

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT01904214

Locations: 🇷🇴
Novartis Investigative Site, Bucuresti, Romania

Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

Phase 3

Withdrawn

Conditions: Psoriasis

Interventions: Biological: Intervention B
Biological: Intervention A
Biological: Placebo

First Posted Date: 2013-07-16

Last Posted Date: 2013-08-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01900782

A Phase I Study of LEE011 in Asian Patients

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: LEE011

First Posted Date: 2013-07-12

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01898845

Locations: 🇯🇵
Novartis Investigative Site, Chuo-ku, Tokyo, Japan

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Secukinumab
Drug: Placebo

First Posted Date: 2013-07-04

Last Posted Date: 2019-06-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 460

Registration Number: NCT01892436

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod
Drug: Interferon beta-1a
Drug: Placebo capsule
Drug: Placebo i.m. injection

First Posted Date: 2013-07-04

Last Posted Date: 2025-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 240

Registration Number: NCT01892722

Locations: 🇺🇸
AMO Corporation, Tallahassee, Florida, United States
🇺🇸
UAB Childrens Hospital Harbor Center Neurology Dept, Birmingham, Alabama, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 9 locations

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Phase 2

Completed

Conditions: Acute Leukaemia

Interventions: Drug: Daunorubicin
Drug: Cytarabine
Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2013-07-02

Last Posted Date: 2019-09-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT01890746

Locations: 🇷🇺
Novartis Investigative Site, Tula, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy